Shilpa Medicare Ltd Share Price
(SHILPAMED)
₹676.5▲7.31%
as on 01:50PM, 18 Mar 2025
🔔 Partnership Alert
Shilpa Medicare's subsidiary, Shilpa Biologicals, partners with mAbTree Biologics AG to co-develop a novel immuno-oncology therapy.
Shilpa Medicare Performance
Day's Low
Day's High
₹628.3Day's Price Range₹710.952 Week's Low
52 Week's High
₹397.9552-Week Price Range₹959.5
| Returns % | |
| 1 Month Return | -1.78 % |
| 3 Month Return | -24.08 % |
| 1 Year Return | + 37.18 % |
| Market Stats | |
| Previous Close | ₹630.40 |
| Open | ₹676.80 |
| Volume | 12.76L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹6,164.74Cr |
Shilpa Medicare Fundamentals
P/E Ratio
67.35
PEG Ratio
7.14
Market Cap
₹6,164.74 Cr
P/B Ratio
1.87
EPS
3.68
Dividend Yield
0Sector
Pharmaceuticals
ROE
1.59
Mutual Fund Holdings of Shilpa Medicare
Shilpa Medicare Analyst Rating
based on 2 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 2 analysts offering long term price targets for Shilpa Medicare. An average target of ₹1208
Source: S&P Global Market Intelligence
Shilpa Medicare Share analysis
Shilpa Medicare price forecast by 2 analysts
Upside of91.62%
High
₹1525
Target
₹1208.00
Low
₹891
Shilpa Medicare target price ₹1208, a slight upside of 91.62% compared to current price of ₹676.5. According to 2 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Shilpa Medicare revenue growth forecast
Expected growth rate Q1, FY2027:0
Forecast
Actual
Including amortisation and stock based compensations
Shilpa Medicare EPS growth forecast
EPS estimate Q1, FY2027:0
Forecast
Actual
Source: S&P Global Market Intelligence
What's happening today
Today's Timeline - Invalid Date
06:19 AM
-Shilpa Biologicals enters binding term sheet with mAbTree Biologics for developing a new biological entity.
09:43 AM
-Shilpa Medicare shares rise 2% after subsidiary partners with mAbTree Biologics for cancer drug development.
11:11 AM
-Shilpa Medicare stock soars 10.46% following strategic partnership announcement with mAbTree Biologics for immuno-oncology therapy.
Today's Timeline - Invalid Date
12:01 PM
-Shilpa Medicare shares surge 10% as subsidiary partners with mAbTree Biologics for novel cancer therapy.
12:32 PM
-Shilpa Medicare stock rises 9.70% after announcing partnership with mAbTree Biologics for immuno-oncology therapy.
Key events for Shilpa Medicare Ltd
Shilpa Medicare Partners for Cancer Therapy Development - 17 Mar, 2025
Shilpa Medicare's subsidiary, Shilpa Biologicals, has partnered with mAbTree Biologics to develop a novel immuno-oncology therapy. Additionally, Shilpa Pharma Lifesciences received zero observations from the US FDA during a recent inspection, marking a successful compliance record.Shilpa Medicare Achieves Second Clean USFDA Inspection - 14 Mar, 2025
Shilpa Medicare's subsidiary, Shilpa Pharma Lifesciences, successfully cleared a USFDA inspection at its Raichur Unit-2 with zero observations, marking its second consecutive clean inspection.Shilpa Medicare Receives FDA Form 483 Observation - 08 Mar, 2025
Shilpa Medicare's Raichur unit received a Form 483 with one observation from the US FDA following an inspection. The company reported a significant increase in Q3 FY25 net profit to Rs 31.78 crore, up from Rs 4.58 crore in Q3 FY24, with revenue rising 11.35% year-on-year.Shilpa Medicare Receives USFDA Observation Notice - 07 Mar, 2025
Shilpa Medicare's subsidiary, Shilpa Pharma Lifesciences, received one procedural observation from the USFDA following an inspection at its Raichur facility from March 3-7, 2025. The company is committed to addressing the observation promptly.
Insights on Shilpa Medicare Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 3 quarters, 14.06 Cr → 31.78 Cr (in ₹), with an average increase of 32.6% per quarter
- POSITIVE IMPACT
Price Rise
In the last 1 year, SHILPAMED stock has moved up by 37.2%
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 9.58% to 9.90% in Dec 2024 quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 61.7% return, outperforming this stock by 24.5%
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 121.9% return, outperforming this stock by 66.0%
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 5.09% to 4.89% in Dec 2024 quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 348.79 Cr → 320.79 Cr (in ₹), with an average decrease of 8.0% per quarter
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 44.33% to 44.23% in Dec 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 37.90% to 37.60% in Dec 2024 quarter
Shilpa Medicare Financials
Shilpa Medicare Index Inclusions
Shilpa Medicare Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 44.23% | ||
| Foreign Institutions | 9.9% | 3.35 | |
| Mutual Funds | 4.89% | ||
| Retail Investors | 37.6% | ||
| Others | 3.37% | 9.02 |
Shilpa Medicare Key Indicators
Shilpa Medicare Valuation
Shilpa Medicare in the last 5 years
Lowest (-6579.29x)
March 28, 2024
Industry (50.70x)
March 17, 2025
Today (67.35x)
March 17, 2025
Highest (503.73x)
February 21, 2023
Shilpa Medicare Earnings and Dividends
Shilpa Medicare Ltd Earnings Results
Shilpa Medicare Ltd’s net profit jumped 593.89% since last year same period to ₹31.78Cr in the Q3 2024-2025. On a quarterly growth basis, Shilpa Medicare Ltd has generated 77.15% jump in its net profits since last 3-months.
Read More about Earnings ResultsShilpa Medicare Ltd Dividends May,2022
In the quarter ending March 2022, Shilpa Medicare Ltd has declared dividend of ₹1.10 - translating a dividend yield of 0.35%.
Read More about Dividends
Shilpa Medicare Technicals Summary
Bearish
Neutral
Bullish
Shilpa Medicare Ltd is currently in a Bearish trading position according to technical analysis indicators.
Shilpa Medicare Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹6,164.74 Cr | 19.5% | 0.53 | ₹31 Cr | ₹1,151 Cr | |
| BUY | ₹28,896.94 Cr | 157.81% | 0.52 | ₹300 Cr | ₹1,051 Cr | |
| BUY | ₹13,639.27 Cr | 49.71% | 0.57 | ₹72 Cr | ₹6,702 Cr | |
| NA | ₹3,805.02 Cr | 3.66% | 0.79 | -₹388 Cr | ₹75 Cr | |
| BUY | ₹12,694.97 Cr | 35.54% | 0.68 | ₹218 Cr | ₹1,296 Cr |
About Shilpa Medicare
Revenue: ₹319.32Cr as on December 2024 (Q4 24)
Net Profit: ₹31.78Cr as on December 2024 (Q4 24)
Listing date: 03 Dec, 2009
Chairperson Name: Omprakash Inani
| Organisation | Shilpa Medicare |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Shilpa Medicare Ltd
What is Shilpa Medicare Ltd price today?
Shilpa Medicare Ltd share price today stands at ₹676.5, Open: ₹676.8, Previous Close: ₹630.4, High: ₹710.9, Low: ₹628.3, 52 Week High: ₹959.5, 52 Week Low: ₹397.95.
How to Buy Shilpa Medicare Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Shilpa Medicare Ltd shares
What are today's traded volumes of Shilpa Medicare Ltd?
Today's traded volume of Shilpa Medicare Ltd(SHILPAMED) is 12.76L.
What is today's market capitalisation of Shilpa Medicare Ltd?
Today's market capitalisation of Shilpa Medicare Ltd(SHILPAMED) is ₹6164.74Cr.
What is the 52 Week High and Low Range of Shilpa Medicare Ltd?
How much percentage Shilpa Medicare Ltd is down from its 52 Week High?
Shilpa Medicare Ltd (SHILPAMED) share price is ₹676.5. It is down -29.49% from its 52 Week High price of ₹959.5
How much percentage Shilpa Medicare Ltd is up from its 52 Week low?
Shilpa Medicare Ltd (SHILPAMED) share price is ₹676.5. It is up 70.00% from its 52 Week Low price of ₹397.95